Naltrexone and Scopolamine Rapidly Reduce Symptoms of Major Depressive Disorder (MDD): A Double Blinded Randomized Controlled Pilot Study

Journals Menu

Follow SCIRP

ISSN Print: 2169-9658
ISSN Online: 2169-9674
www.scirp.org/journal/ojd
E-mail: ojd@scirp.org

"Naltrexone and Scopolamine Rapidly Reduce Symptoms of Major Depressive Disorder (MDD): A Double Blinded Randomized Controlled Pilot Study"
written by N. Taub,
published by Open Journal of Depression, Vol.8 No.1, 2019

has been cited by the following article(s):

[1]	Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc …
	… Disease and Treatment, 2023

[2]	Antidepressant effects of the muscarinic receptor antagonist scopolamine: clinical and preclinical review
	New Rapid-acting …, 2021

[3]	The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions.
	2020

[4]	The antidepressant efficacy of the muscarinic antagonist scopolamine: past findings and future directions
	2020

[1]	Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc Analysis Neuropsychiatric Disease and Treatment, 2023 DOI:10.2147/NDT.S408794

[2]	New Rapid-acting Antidepressants Contemporary Clinical Neuroscience, 2021 DOI:10.1007/978-3-030-79790-4_8

[3]	Rapid Acting Antidepressants Advances in Pharmacology, 2020 DOI:10.1016/bs.apha.2020.04.002

Follow SCIRP